GenSight Biologics S.A.

Capital/Financing Update • Aug 11, 2016

Press release

GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie

Paris, August 11, 2016 – GenSight Biologics (Euronext: SIGHT, FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announces that the company entrusts Oddo & Cie with the implementation of a liquidity contract in accordance with the Charter of Ethics established by the AMAFI of March 8, 2011 and approved by the decision of the Autorité des Marchés Financiers of 21 March 2011.

For the implementation of this contract, the following resources have been allocated to the liquidity account:

€300 000 (three hundred thousand euros)

Contacts

GenSight Biologics Thomas Gidoin Chief Financial Officer tgidoin@gensight-biologics.com +33 (0) 6 01 36 35 43

NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55

NewCap Media Relations Annie-Florence Loyer afloyer@newcap.fr +33 (0)1 44 71 94 93

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics' pipeline leverages two core technology platforms, Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber's Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible vision loss in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to offer patients a sustainable functional visual recovery with a single treatment to each eye through an intravitreal injection.